Gayle SS - Search Results

1

Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells.

Gayle SS, Sahni JM, Webb BM, Weber-Bonk KL, Shively MS, Spina R, Bar EE, Summers MK, Keri RA. Gayle SS, et al. J Biol Chem. 2019 Jan 18;294(3):875-886. doi: 10.1074/jbc.RA118.004712. Epub 2018 Nov 27. J Biol Chem. 2019. PMID: 30482844 Free PMC article.

2

Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.

Sahni JM, Gayle SS, Bonk KL, Vite LC, Yori JL, Webb B, Ramos EK, Seachrist DD, Landis MD, Chang JC, Bradner JE, Keri RA. Sahni JM, et al. Among authors: gayle ss. J Biol Chem. 2016 Nov 4;291(45):23756-23768. doi: 10.1074/jbc.M116.738666. Epub 2016 Sep 20. J Biol Chem. 2016. PMID: 27650498 Free PMC article.

3

Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET Inhibitors.

Sahni JM, Gayle SS, Webb BM, Weber-Bonk KL, Seachrist DD, Singh S, Sizemore ST, Restrepo NA, Bebek G, Scacheri PC, Varadan V, Summers MK, Keri RA. Sahni JM, et al. Among authors: gayle ss. Cancer Res. 2017 Oct 1;77(19):5395-5408. doi: 10.1158/0008-5472.CAN-17-1571. Epub 2017 Aug 14. Cancer Res. 2017. PMID: 28807940 Free PMC article.

4

BETi induction of mitotic catastrophe: towing the LIN9.

Gayle SS, Sahni JM, Keri RA. Gayle SS, et al. Oncoscience. 2017 Oct 23;4(9-10):128-130. doi: 10.18632/oncoscience.372. eCollection 2017 Sep. Oncoscience. 2017. PMID: 29142903 Free PMC article. No abstract available.

5

Correction: Bromodomain and extraterminal protein inhibition blocks growth of triple-negative breast cancers through the suppression of aurora kinases.

Sahni JM, Gayle SS, Bonk KLW, Vite LC, Yori JL, Webb B, Ramos EK, Seachrist DD, Landis MD, Chang JC, Bradner JE, Keri RA. Sahni JM, et al. Among authors: gayle ss. J Biol Chem. 2020 Jul 3;295(27):9266. doi: 10.1074/jbc.AAC120.014699. J Biol Chem. 2020. PMID: 32620694 Free PMC article. No abstract available.

6

[No title available]

[No authors listed] [No authors listed] PMID: 33516519

7

MEK inhibition increases lapatinib sensitivity via modulation of FOXM1.

Gayle SS, Castellino RC, Buss MC, Nahta R. Gayle SS, et al. Curr Med Chem. 2013;20(19):2486-99. doi: 10.2174/0929867311320190008. Curr Med Chem. 2013. PMID: 23531216 Free PMC article.

8

Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.

Gayle SS, Arnold SL, O'Regan RM, Nahta R. Gayle SS, et al. Anticancer Agents Med Chem. 2012 Feb;12(2):151-62. doi: 10.2174/187152012799015002. Anticancer Agents Med Chem. 2012. PMID: 22043997 Free PMC article.

9

Equity, diversity, and inclusion at the Global Alliance for Genomics and Health.

Skantharajah N, Baichoo S, Boughtwood TF, Casas-Silva E, Chandrasekharan S, Dave SM, Fakhro KA, Falcon de Vargas AB, Gayle SS, Gupta VK, Hendricks-Sturrup R, Hobb AE, Li S, Llamas B, Lopez-Correa C, Machirori M, Melendez-Zajgla J, Millner MA, Page AJH, Paglione LD, Raven-Adams MC, Smith L, Thomas EM, Kumuthini J, Corpas M. Skantharajah N, et al. Among authors: gayle ss. Cell Genom. 2023 Aug 24;3(10):100386. doi: 10.1016/j.xgen.2023.100386. eCollection 2023 Oct 11. Cell Genom. 2023. PMID: 37868041 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters